Home > Boards > US Listed > Biotechs > MERSANA THERAPEUTICS, INC. (MRSN)

Mersana...after ASCO...

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
jaybe Member Profile
 
Followed By 5
Posts 285
Boards Moderated 0
Alias Born 05/29/11
160x600 placeholder
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 9/16/2021 6:02:00 AM
Is Mersana Stock a Buy Right Now? This Is What You Need to Know TipRanks - 9/13/2021 4:20:16 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/10/2021 7:51:32 AM
Mersana Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire Inc. - 9/7/2021 8:00:00 AM
Mersana Therapeutics to Provide Update on the Progress of its UpRi Clinical Development Strategy and Report Interim Data from the Ovarian Cancer Expansion Cohort of the UpRi Phase I Study GlobeNewswire Inc. - 9/1/2021 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/24/2021 4:31:57 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/18/2021 4:32:54 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 8/18/2021 4:31:25 PM
Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire Inc. - 8/18/2021 4:05:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/16/2021 8:17:02 AM
Mersana Therapeutics Announces Appointment of Tushar Misra, Ph.D., as Chief Manufacturing Officer GlobeNewswire Inc. - 8/16/2021 8:00:00 AM
Mersana Therapeutics EPS misses by $0.09 Seeking Alpha - 8/6/2021 6:04:38 AM
Mersana Therapeutics Announces Second Quarter 2021 Financial Results and Provides Business Update GlobeNewswire Inc. - 8/6/2021 6:00:00 AM
Mersana Therapeutics to Present at the 12th Annual Wedbush PacGrow Healthcare Conference GlobeNewswire Inc. - 8/4/2021 8:00:00 AM
Mersana Therapeutics to Host Conference Call Announcing Second Quarter 2021 Financial Results and Business Updates GlobeNewswire Inc. - 7/30/2021 8:00:00 AM
Mersana Therapeutics Announces Initiation of the UPGRADE Phase 1 Platinum Combination Cohort for UpRi in Platinum-Sensitive Ovarian Cancer GlobeNewswire Inc. - 7/28/2021 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/2/2021 4:32:28 PM
The Bottom Is in for These 2 Stocks? Analysts Say ‘Buy’ TipRanks - 6/29/2021 11:13:37 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/23/2021 4:31:46 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/17/2021 6:31:32 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/15/2021 6:36:40 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/15/2021 6:04:31 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/15/2021 6:04:16 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/15/2021 6:03:52 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/15/2021 6:02:44 PM
jaybe   Thursday, 06/07/18 12:33:33 PM
Re: None
Post # of 42 
Mersana...after ASCO...

Looks like a long summer for Mersana. The ASCO data was a real cliff-hanger, responses trending in the right direction, but AEs showing up to, so woefully inconclusive. Doses 8-10 will take ~6-8 weeks each so any meaningful update will be at ENA'18 in mid-November, which is also likely the venue for unveiling the 3rd candidate. Patent app for 3rd drug should publish by end of summer.

In other news, DS-8201 continues to crush the competition and raise the bar for XMT-1522. ASCO data showed 50% ORR for Her-2 low MBC patients. Mersana will need to approach this number with some differentiation in order to compete.

Hopefully XMT-1536 will also reach MTD this year, but readout would be AACR in April at earliest.



Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences